| 10.2519 -0.128 (-1.23%) | 11-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.32 |
1-year : | 14.33 |
| Resists | First : | 11.4 |
Second : | 12.27 |
| Pivot price | 10.88 |
|||
| Supports | First : | 10.01 |
Second : | 8.32 |
| MAs | MA(5) : | 10.38 |
MA(20) : | 11.05 |
| MA(100) : | 13.83 |
MA(250) : | 16.27 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 9.5 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 25.87 | Low : | 10.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIS ] has closed above bottom band by 10.1%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.6 - 10.66 | 10.66 - 10.71 |
| Low: | 9.83 - 9.91 | 9.91 - 9.98 |
| Close: | 10.13 - 10.25 | 10.25 - 10.35 |
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Wed, 14 May 2025
Top Performing Leveraged/Inverse ETFs: 05/11/2025 - ETF Trends
Tue, 19 Nov 2024
Top Performing Leveraged/Inverse ETFs: 11/17/2024 - ETF Trends
Thu, 16 Feb 2023
ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Sees Significant Growth in Short Interest - 富途牛牛
Mon, 05 Dec 2022
3 ETFs in “Oversold” Territory to Start the Week - ETF Trends
Thu, 14 Jul 2022
ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Up 644.1% in June - 富途牛牛
Wed, 06 Jul 2022
Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Decreases By 21.9% - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|